Logo image of XRTX.CA

XORTX THERAPEUTICS INC (XRTX.CA) Stock Overview

Canada - TSX-V:XRTX - CA98420Q3061 - Common Stock

1.22 CAD
+0.11 (+9.91%)
Last: 9/23/2025, 7:00:00 PM

XRTX.CA Key Statistics, Chart & Performance

Key Statistics
52 Week High3.46
52 Week Low0.91
Market Cap6.36M
Shares5.21M
Float5.08M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.4
PEN/A
Fwd PEN/A
Earnings (Next)11-12 2025-11-12
IPO09-30 2015-09-30
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


XRTX.CA short term performance overview.The bars show the price performance of XRTX.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 -10

XRTX.CA long term performance overview.The bars show the price performance of XRTX.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of XRTX.CA is 1.22 CAD. In the past month the price decreased by -3.17%. In the past year, price decreased by -41.9%.

XORTX THERAPEUTICS INC / XRTX Daily stock chart

XRTX.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
BHC.CA BAUSCH HEALTH COS INC 1.78 3.45B
TLRY.CA TILRAY BRANDS INC N/A 1.93B
CRON.CA CRONOS GROUP INC 52 1.39B
DHT-UN.CA DRI HEALTHCARE TRUST 6.6 783.15M
GUD.CA KNIGHT THERAPEUTICS INC N/A 601.89M
DHT-U.CA DRI HEALTHCARE TRUST 4.89 580.05M
WEED.CA CANOPY GROWTH CORP N/A 486.98M
HITI.CA HIGH TIDE INC N/A 435.40M
CPH.CA CIPHER PHARMACEUTICALS INC 25.42 411.96M
TSND.CA TERRASCEND CORP N/A 399.32M
ACB.CA AURORA CANNABIS INC N/A 390.38M
OGI.CA ORGANIGRAM GLOBAL INC N/A 334.48M

About XRTX.CA

Company Profile

XRTX logo image XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Calgary, Alberta. The company went IPO on 2015-09-30. The firm is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. The company has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. The company is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.

Company Info

XORTX THERAPEUTICS INC

3710 - 33rd Street NW

Calgary ALBERTA CA

Employees: 3

XRTX Company Website

XRTX Investor Relations

Phone: 14034557727

XORTX THERAPEUTICS INC / XRTX.CA FAQ

What is the stock price of XORTX THERAPEUTICS INC today?

The current stock price of XRTX.CA is 1.22 CAD. The price increased by 9.91% in the last trading session.


What is the ticker symbol for XORTX THERAPEUTICS INC stock?

The exchange symbol of XORTX THERAPEUTICS INC is XRTX and it is listed on the TSX Venture Exchange exchange.


On which exchange is XRTX.CA stock listed?

XRTX.CA stock is listed on the TSX Venture Exchange exchange.


What is XORTX THERAPEUTICS INC worth?

XORTX THERAPEUTICS INC (XRTX.CA) has a market capitalization of 6.36M CAD. This makes XRTX.CA a Nano Cap stock.


How many employees does XORTX THERAPEUTICS INC have?

XORTX THERAPEUTICS INC (XRTX.CA) currently has 3 employees.


What are the support and resistance levels for XORTX THERAPEUTICS INC (XRTX.CA) stock?

XORTX THERAPEUTICS INC (XRTX.CA) has a support level at 1.22 and a resistance level at 1.25. Check the full technical report for a detailed analysis of XRTX.CA support and resistance levels.


Should I buy XORTX THERAPEUTICS INC (XRTX.CA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does XORTX THERAPEUTICS INC (XRTX.CA) stock pay dividends?

XRTX.CA does not pay a dividend.


When does XORTX THERAPEUTICS INC (XRTX.CA) report earnings?

XORTX THERAPEUTICS INC (XRTX.CA) will report earnings on 2025-11-12.


What is the Price/Earnings (PE) ratio of XORTX THERAPEUTICS INC (XRTX.CA)?

XORTX THERAPEUTICS INC (XRTX.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.4).


XRTX.CA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

XRTX.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to XRTX.CA. While XRTX.CA has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

XRTX.CA Financial Highlights

Over the last trailing twelve months XRTX.CA reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS increased by 79.15% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -28.38%
ROE -36.23%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%84.95%
Sales Q2Q%N/A
EPS 1Y (TTM)79.15%
Revenue 1Y (TTM)N/A

XRTX.CA Forecast & Estimates


Analysts
Analysts80
Price TargetN/A
EPS Next Y-11.64%
Revenue Next YearN/A

XRTX.CA Ownership

Ownership
Inst Owners0.01%
Ins Owners3.38%
Short Float %N/A
Short RatioN/A